Baby Powder Cancer Lawsuit Spurs Indian FDA Review

In the wake of the first talcum powder ovarian cancer lawsuit to be awarded damages in trial, the Indian Food and Drug Administration has announced it will begin to sample Johnson & Johnson baby powder products to assess a possible link to ovarian cancer.

Monday, March 28, 2016 - The Indian Food and Drug Administration has called for talcum powder cancer samples from Johnson & Johnson (J&J) in the wake of the $72 million jury verdict found in favor of an American talcum powder cancer lawsuit plaintiff. The Food and Drug Administration, much like the one in the U.S., is the lead drug regulation body in the Indian government and is now taking steps to investigate a possible talcum powder ovarian cancer connection related to the J&J products.

The St. Louis talcum powder ovarian cancer lawsuit that took place in February has sparked interest worldwide in the potential side effects caused by the widely popular J&J baby powder products. The the baby powder cancer attorneys representing the plaintiff presented evidence that they claimed proved that J&J knowingly decided against affixing warning labels to their talcum powder products with full knowledge that research was being conducted into a talcum powder ovarian cancer link. The attorneys also provided internal documents that showed the company had been warned by doctors consulting on its behalf of the dangers of ignoring the ovarian cancer link to their baby powder products.

The evidence was given a significant stamp of approval by the jury, which awarded the plaintiff $10 million in compensatory damages and hit J&J hard with a $62 million punitive penalty. The legitimized evidence presented during the talcum powder cancer lawsuits in America is now catalyzing governments around the world to take notice of J&J and their baby powder products. The Indian FDA has ordered sample testing of J&J talcum powder products in the wake of the baby powder ovarian cancer lawsuit verdict. The samples taken will be tested to discern whether they fall under the Indian Drug and Cosmetic Act laws.

J&J has been attempting to change the narrative since the talcum powder ovarian cancer lawsuit concluded in St. Louis. The company has claimed that their baby powder products are supported by research they have found that supports the absence of a connection between talcum powder and ovarian cancer. The company has factories worldwide, including in India, and will likely have to do more than present the same evidence they did at the talcum powder cancer lawsuit trial to keep their distributors and consumers from switching to cornstarch based drying agents. The cornstarch products have been recommended in studies that found troubling connections between talcum powder and ovarian cancer.

J&J is the world's largest health care product manufacturer and baby powder is one of its essential products. The company also manufactures cornstarch baby powder, but in the trial a baby powder lawyer representing the plaintiff noted that the company had pushed their talcum powder products on poor and minority communities. The stain of the company's practices concerning their baby powder may persuade a consumer to not switch to J&J cornstarch baby powder, but to abandon the company all together. After the trial of the first talcum powder ovarian cancer lawsuit to be awarded damages, the Indian Food and Drug Administration will continue to look into the company to discover whether abandoning J&J would be a smart decision for the country's consumers to make.

Information provided by TalcumPowderCancerLawsuit.com, a website devoted to providing news about talcum powder ovarian cancer lawsuits, as well as medical research and findings.